Table 3.

Clinical characteristics of patients who progressed during follow-up.

rhTPO group				Non-rhTPO group
	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 6
Age (years)	41	58	67	46	62	52	48
Sex	M	M	F	F	F	F	M
R-IPSS	Int-1	Int-1	Int-1	Int-1	Low	Int-1	Low
Baseline
Karyotype	46,XY [20]	46,XY [20]	46,XX [20]	46,XX [20]	46,XX [20]	46,XX [20]	46,XY [20]
Bone marrow blasts (%)	<5	<5	<2	<5	<5	<5	<2
ANC (×109/μl)	1.25	2.22	0.3	1.77	1.81	0.77	4.5
Hemoglobin (g/L)	69	54	72	45	98	66	101
Platelets (×109/L)	13	16	6	8	21	6	16
Disease progression
Karyotype	46,XY [20]	46,XY, [20]	46,XX,-7 [20]	46,XX [20]	46,XX [20]	46,XX [20]	46,XY [20]
Bone marrow blasts (%)	<5	<2	5	<5	<5	<5	<2
ANC (×109/μl)	0.77	3.66	0.56	1.96	2.81	1.77	4.5
Hemoglobin (g/L)	67	54	65	68	104	73	190
Platelets (×109/L)	5	2	5	3	10	2	5
Time to progression (months)	9	6	9	9	6	7	6
Present status	Alive	Dead	Alive	Alive	Alive	Alive	Alive

rhTPO, recombinant human thrombopoietin; ANC, absolute neutrophil count; Int-1, intermediate 1; Int-2, intermediate 2.